The discovery of recurrent mutations in the gene DNMT3A and its possible prognostic implications can provide valuable information for risk stratification for patients with AML and represents a valuable tool for making therapeutic decisions. This evidence concerns the gene DNMT3A and acute myeloid leukemia.